{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-054807","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.274960+00:00","generated_at":"2026-06-16T03:42:29.844753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiniksa raises ARCALYST FY2023 guidance; Q1 revenue $48.3M, net loss narrows","bullets":["ARCALYST Q1 net product revenue $42.7M; FY2023 guidance raised to $200-215M (~69% YoY growth at midpoint).","Net loss improved to $12.3M from $25.2M YoY; total revenue $48.3M vs $32.2M.","Cash & short-term investments $187.5M, no debt; cash runway now expected into at least 2026.","Final cohort of KPL-404 Phase 2 RA trial enrolling; data expected 1H 2024.","Over 1,000 prescribers written ARCALYST scripts since launch; payer approval rate >90%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-054807","json":"https://secwatch.observer/filing/0001104659-23-054807.json","markdown":"https://secwatch.observer/filing/0001104659-23-054807.md","text":"https://secwatch.observer/filing/0001104659-23-054807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923054807/0001104659-23-054807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923054807/tm2314130d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:42:29.844753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"385c896de2a1ba61c495c98530494df438340caa","claim":"Kiniksa Pharmaceuticals International, plc reported first quarter 2023 results: revenue $48.3 million, net income $12.3 million. Guidance raised.","evidence_excerpt":"diseases where the granulocyte macrophage colony stimulating factor (GM-CSF) mechanism has been implicated. Financial Results · Total revenue for the first quarter of 2023 was $48.3 million, compared to $32.2 million for the first quarter of 2022. - Total revenue for the first quarter of 2023 included $42.7 million in ARCALYST net product revenue and $5.7 million in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465923054807/0001104659-23-054807-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"$48.3 million"},{"label":"Net income","value":"$12.3 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}